IP Library › Granted Patent US 10,253,075
Granted Patent B2
US 10,253,075 · App. 15/121,525 · Granted Apr 9, 2019

WT1 antigenic polypeptide, and anti-tumor agent containing said polypeptide

Inventors: Takashi Nishimura (Sapporo, JP); Yuji Heike (Chuo-ku, JP); Yuji Togashi (Sapporo, JP)
Assignee: TELLA, INC.
C07K14/4748A61K39/0011C07K7/06C07K7/08C07K14/001C12N5/0636A61K38/00A61K39/00A61K2039/5158A61K2039/57C07K2319/00C12N2501/998C12N2502/1121
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,253,075
App. No.
15/121,525
Granted
Apr 9, 2019
Kind
B2
Abstract

[Problem] To provide a polypeptide which enables stimulation of numerous T cells of different derivation, and to induce strong immunological response against numerous types of cancers. [Solution] Provided is a fused polypeptide that includes a helper epitope derived from the WT1 protein, and a killer epitope derived from the WT1 protein, wherein the polypeptide includes a total of 3 to 6 of the helper epitopes and the killer epitopes per molecule of the fused polypeptide.

Claims (6)

1. A polypeptide consisting of the amino acid sequence of SEQ ID NO: 47 or 48.

2. The polypeptide according to claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 47.

3. The polypeptide according to claim 1 , wherein the polypeptide consists of the amino acid sequence of SEQ ID NO: 48.

4. An anti-tumor agent comprising the polypeptide according to claim 1 as an active ingredient.

5. The anti-tumor agent according to claim 4 , further comprising antigen-presenting cells.

6. A method for in vitro producing T cells that produce a cytokine against tumor cells expressing a WT1 protein, comprising (a) incubating in vitro the polypeptide according to claim 1 with mononuclear cells, and (b) incubating the mononuclear cells from step (a) with antigen presenting cells.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: NISHIMURA, TAKASHI
To: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
Reel/Frame 039555/0137 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: TOGASHI, YUJI
To: BIOIMMULANCE CO., LTD.
Reel/Frame 039555/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
To: BIOIMMULANCE CO., LTD.
Reel/Frame 039555/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: NATIONAL CANCER CENTER
To: BIOIMMULANCE CO., LTD.
Reel/Frame 039555/0181 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: BIOIMMULANCE CO., LTD.
To: TELLA, INC.
Reel/Frame 039555/0212 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2016
From: HEIKE, YUJI
To: NATIONAL CANCER CENTER
Reel/Frame 039847/0857 →
Priority Claims (1)
JP 2014-035893 · Feb 26, 2014 · national
Continuity (1)
Related Publication 20160362465A1 · Dec 15, 2016